The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy

Addiction

Volumn 106, Issue 10, 2011, Pages 1835-1845

  Javitz, Harold S ^a   Swan, Gary E ^a   Lerman, Caryn ^b  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bupropion; Hierarchical linear modeling; Nicotine replacement therapy; Smoking cessation; Smoking withdrawal dynamics; Smoking withdrawal symptom variability; Urge to smoke; Withdrawal symptom trajectories; Withdrawal symptoms

Indexed keywords

AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; NICOTINE; NICOTINIC AGENT; PLACEBO;

ARTICLE; BODY MASS; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEGRO; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SELF REPORT; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; STATISTICAL MODEL; STATISTICS; TIME; TRANSDERMAL PATCH; WITHDRAWAL SYNDROME;

ADMINISTRATION, INTRANASAL; AFRICAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BUPROPION; DOPAMINE UPTAKE INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PLACEBOS; RECURRENCE; SELF REPORT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TRANSDERMAL PATCH;

EID: 80052724219     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03495.x     Document Type: Article

References (25)

1. Piasecki T. M. Relapse to smoking. Clin Psychol Rev 2006; 26: 196-215.
2. Piasecki T. M., Jorenby D. E., Smith S. S., Fiore M. C., Baker T. B. Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 2003; 112: 3-13.
3. Piasecki T. M., Jorenby D. E., Smith S. S., Fiore M. C., Baker T. B. Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations. J Abnorm Psychol 2003; 112: 14-27.
4. Piasecki T. M., Jorenby D. E., Smith S. S., Fiore M. C., Baker T. B. Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity. Exp Clin Psychopharmacol 2003; 11: 276-85.
5. Henningfield J. E., Shiffman S., Ferguson S. G., Gritz E. R. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009; 123: 1-16.
6. Skinner M. D., Aubin H. J. Craving's place in addiction theory: contributions of the major models. Neurosci Biobehav Rev 2010; 34: 606-23.
7. Lerman C., Tyndale R., Patterson F., Wileyto E. P., Shields P. G., Pinto A. etal. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600-8.
8. Lerman C., Jepson C., Wileyto P. E., Epstein L. H., Rukstalis M., Patterson F. etal. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006; 31: 231-42.
9. Patterson F., Schnoll R., Wileyto E., Pinto A., Epstein L., Shields P. etal. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 84: 320-5.
10. Shiffman S., Patten C., Gwaltney C., Paty J., Gnys M., Kassel J. etal. Natural history of nicotine withdrawal. Addiction 2006; 101: 1822-32.
11. Gilbert D. G., Zuo Y., Rabinovich N. E., Riise H., Needham R., Huggenvik J. I. Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. J Abnorm Psychol 2009; 118: 322-34. PMID: 19413407.
12. Dale L. C., Glover E. D., Sachs D. P., Schroeder D. R., Offord K. P., Croghan I. T. etal. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001; 119: 1357-64.
13. Fiore M. C., Kenford S. L., Jorenby D. E., Wetter D. W., Smith S. S., Baker T. B. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994; 105: 524-33.
14. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C. etal. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
15. Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R. etal. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.
16. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 1991; 266: 3133-8.
17. Perkins K. A., Gerlach D., Vender J., Grobe J., Meeker J., Hutchison S. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res 2001; 3: 141-50.
18. Evans S. E., Blank M., Sams C., Weaver M. F., Eissenberg T. Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender. Exp Clin Psychopharmacol 2006; 14: 121-35.
19. Rohsenow D. J., Monti P. M., Hutchison K. E., Swift R. M., MacKinnon S. V., Sirota A. D. etal. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol 2007; 15: 81-92.
20. Weinstein A., Greif J., Yemini Z., Lerman H., Weizman A., Even-Sapir E. Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion. J Psychopharmacol 2010; 24: 829-38.
21. Schneider N. G., Cortner C., Gould J. L., Koury M. A., Olmstead R. E. Comparison of craving and withdrawal among four combination nicotine treatments. Hum Psychopharmacol 2008; 23: 513-7.
22. Brody A. L., Mandelkern M. A., Lee G., Smith E., Sadeghi M., Saxena S. etal. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res 2004; 130: 269-81.
23. Verheul R., van den Brink W., Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol 1999; 34: 197-222.
24. Robinson T. E., Berridge K. C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
25. McCarthy D. E., Piasecki T. M., Fiore M. C., Baker T. B. Life before and after quitting smoking: an electronic diary study. J Abnorm Psychol 2006; 115: 454-66.